.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

LUMIGAN Drug Profile

« Back to Dashboard
Lumigan is a drug marketed by Allergan and is included in two NDAs. It is available from two suppliers. There are twelve patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-one patent family members in twenty-one countries.

The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the bimatoprost profile page.

Summary for Tradename: LUMIGAN

Patents:12
Applicants:1
NDAs:2
Suppliers / Packagers: see list2

Pharmacology for Tradename: LUMIGAN

Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog

Clinical Trials for: LUMIGAN

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 2001DISCNNo<disabled><disabled>
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYes8,524,777<disabled> <disabled>
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYes8,933,120<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LUMIGAN

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 20105,688,819<disabled>
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 20015,688,819<disabled>
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 20108,017,655<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LUMIGAN

Drugname Dosage Strength RLD Submissiondate
bimatoprostOphthalmic Solution0.01%Lumigan4/5/2011
bimatoprostOphthalmic Solution0.03%Lumigan12/22/2008

International Patent Family for Tradename: LUMIGAN

Country Document Number Estimated Expiration
China102240292<disabled in preview>
Russian Federation2007133919<disabled in preview>
Israel185744<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LUMIGAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00099Netherlands<disabled>PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
C0033France<disabled>PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
C/GB02/035United Kingdom<disabled>PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc